[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Rises As Market Takes a Dip: Key Facts",
    "summary": "Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=2152a9070742ccf3fc4ace28c0468ab916ba16f3241510fae63d37666843ec1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743717009,
      "headline": "Amgen (AMGN) Rises As Market Takes a Dip: Key Facts",
      "id": 133704788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=2152a9070742ccf3fc4ace28c0468ab916ba16f3241510fae63d37666843ec1c"
    }
  },
  {
    "ts": null,
    "headline": "Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday",
    "summary": "As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday.  Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech.  Compared to the S&P 500's (SNPINDEX: ^GSPC) 4.8% tumble, Catalyst Pharmaceuticals' (NASDAQ: CPRX) 1.5% drop was mild, as was Veeva Systems' (NYSE: VEEV) 2% slide.",
    "url": "https://finnhub.io/api/news?id=ae0aa4c3b66914d300870aee0a92fbe5fb9ba9e4b1f6045399b83d4496023fff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743713448,
      "headline": "Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday",
      "id": 133704790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday.  Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech.  Compared to the S&P 500's (SNPINDEX: ^GSPC) 4.8% tumble, Catalyst Pharmaceuticals' (NASDAQ: CPRX) 1.5% drop was mild, as was Veeva Systems' (NYSE: VEEV) 2% slide.",
      "url": "https://finnhub.io/api/news?id=ae0aa4c3b66914d300870aee0a92fbe5fb9ba9e4b1f6045399b83d4496023fff"
    }
  },
  {
    "ts": null,
    "headline": "UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE",
    "summary": "Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine's potential",
    "url": "https://finnhub.io/api/news?id=f7dfb14cf81325fa363930774f815bad0813607fcb94205f68983ca41e93ef5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743708900,
      "headline": "UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE",
      "id": 133704791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine's potential",
      "url": "https://finnhub.io/api/news?id=f7dfb14cf81325fa363930774f815bad0813607fcb94205f68983ca41e93ef5f"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves Amgen's Uplizna as first treatment for rare immune disorder",
    "summary": "(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.  The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in which an overactive immune system can lead to inflammation and scarring in various organs, including the pancreas, liver and kidneys.  \"By removing or depleting these B cells throughout the body, both in the circulating blood and in the tissue, there's a chance for Uplizna to confer a real benefit,\" said Jay Bradner, Amgen's head of research and development.",
    "url": "https://finnhub.io/api/news?id=4b1595423ca27d1f158062bf48d955c06b590b756b63bbdf21c7968a19efcdbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743706188,
      "headline": "US FDA approves Amgen's Uplizna as first treatment for rare immune disorder",
      "id": 133704793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.  The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in which an overactive immune system can lead to inflammation and scarring in various organs, including the pancreas, liver and kidneys.  \"By removing or depleting these B cells throughout the body, both in the circulating blood and in the tissue, there's a chance for Uplizna to confer a real benefit,\" said Jay Bradner, Amgen's head of research and development.",
      "url": "https://finnhub.io/api/news?id=4b1595423ca27d1f158062bf48d955c06b590b756b63bbdf21c7968a19efcdbc"
    }
  },
  {
    "ts": null,
    "headline": "Amgen : First FDA Approval of Its Kind for People Living With IgG4-Related Disease",
    "summary": "Cracking the code on rare immune-mediated diseases has been a challenge for the scientific community. This highly complex area of human biology encompasses a range of diseases caused by immune...",
    "url": "https://finnhub.io/api/news?id=c71fec636140a067ecbd2b9a3da29279e0bf2ab605ef83a9c234e14373f5fc06",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743702088,
      "headline": "Amgen : First FDA Approval of Its Kind for People Living With IgG4-Related Disease",
      "id": 133700199,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Cracking the code on rare immune-mediated diseases has been a challenge for the scientific community. This highly complex area of human biology encompasses a range of diseases caused by immune...",
      "url": "https://finnhub.io/api/news?id=c71fec636140a067ecbd2b9a3da29279e0bf2ab605ef83a9c234e14373f5fc06"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=8de6c1fc5a7c74949f924b301aa3404df777fdfa0afdd09392f32b407d39d933",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743698040,
      "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 133707393,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=8de6c1fc5a7c74949f924b301aa3404df777fdfa0afdd09392f32b407d39d933"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
    "summary": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
    "url": "https://finnhub.io/api/news?id=9201434bddd814d56ee9eeb219358f350bdede42fd82155c651e1734a1f6d4b9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743697611,
      "headline": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
      "id": 133705729,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
      "url": "https://finnhub.io/api/news?id=9201434bddd814d56ee9eeb219358f350bdede42fd82155c651e1734a1f6d4b9"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna",
    "summary": "By Josh Beckerman Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday...",
    "url": "https://finnhub.io/api/news?id=2f2c92d240f72be09e21c5d7c34d9a415da273e32c677a356d8fc72d06ef9657",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743697586,
      "headline": "FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna",
      "id": 133699864,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Josh Beckerman Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday...",
      "url": "https://finnhub.io/api/news?id=2f2c92d240f72be09e21c5d7c34d9a415da273e32c677a356d8fc72d06ef9657"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).",
    "url": "https://finnhub.io/api/news?id=f5fd93fd56e5b7b9ca7623b8b7214c2216284672bd9de69eac3336dd31fb19d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743671314,
      "headline": "Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks",
      "id": 133697756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).",
      "url": "https://finnhub.io/api/news?id=f5fd93fd56e5b7b9ca7623b8b7214c2216284672bd9de69eac3336dd31fb19d3"
    }
  },
  {
    "ts": null,
    "headline": "Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now",
    "summary": "As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year.  On the contrary -- this can be an optimal time to score some deals and investments you can hang on to for the long haul.  If you've got $5,000 you can afford to invest in the stock market today, three stocks you'll want to consider loading up on right now are Amgen (NASDAQ: AMGN), PayPal (NASDAQ: PYPL), and Baidu (NASDAQ: BIDU).",
    "url": "https://finnhub.io/api/news?id=62a912a014dd2dcdb62d8153c1bfd69638eafc8eeefead9b74b46ee45379ccc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743671100,
      "headline": "Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now",
      "id": 133697757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year.  On the contrary -- this can be an optimal time to score some deals and investments you can hang on to for the long haul.  If you've got $5,000 you can afford to invest in the stock market today, three stocks you'll want to consider loading up on right now are Amgen (NASDAQ: AMGN), PayPal (NASDAQ: PYPL), and Baidu (NASDAQ: BIDU).",
      "url": "https://finnhub.io/api/news?id=62a912a014dd2dcdb62d8153c1bfd69638eafc8eeefead9b74b46ee45379ccc1"
    }
  },
  {
    "ts": null,
    "headline": "Pharma stocks survive market rout on tariff exemption, but uncertainty continues",
    "summary": "LONDON/BENGALURU -Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it...",
    "url": "https://finnhub.io/api/news?id=4ffde5d3c8c20d399be9f6a098d4ec77378206209937a91212051d0456b12110",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743662213,
      "headline": "Pharma stocks survive market rout on tariff exemption, but uncertainty continues",
      "id": 133695780,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "LONDON/BENGALURU -Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it...",
      "url": "https://finnhub.io/api/news?id=4ffde5d3c8c20d399be9f6a098d4ec77378206209937a91212051d0456b12110"
    }
  }
]